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Summary
Cachexia contributes to nearly a third of all cancer deaths, yet the mechanisms underlying skeletal muscle wasting in this
syndrome remain poorly defined. We report that tumor-induced alterations in the muscular dystrophy-associated
dystrophin glycoprotein complex (DGC) represent a key early event in cachexia. Muscles from tumor-bearing mice exhib-
ited membrane abnormalities accompanied by reduced levels of dystrophin and increased glycosylation on DGC proteins.
Wasting was accentuated in tumor mdx mice lacking a DGC but spared in dystrophin transgenic mice that blocked induc-
tion of muscle E3 ubiquitin ligases. Furthermore, DGC deregulation correlated positively with cachexia in patients with
gastrointestinal cancers. Based on these results, we propose that, similar to muscular dystrophy, DGC dysfunction plays
a critical role in cancer-induced wasting.
Introduction
Cachexia is a severe, debilitating consequence of cancer that
is estimated to contribute up to a third of all cancer deaths
(Argiles et al., 2003; Tisdale, 2002). This syndrome correlates
with poor prognosis and severely compromises quality of life.
Cachexia physically weakens patients to a state of immobility
stemming from anorexia, asthenia, and anemia, and response
to standard treatment is usually poor (Andreyev et al., 1998).
Wasting results from severe weight loss due to depletion of
both adipose tissue and lean muscle mass. However, it is the
chronic loss of muscle that most often disrupts the physiologi-
cal functions of patients, culminating in significantly shortened
survival time (van Eys, 1985).
Though the molecular mechanisms of cancer cachexia re-
main ill defined, research from the last 2 decades has made
significant progress on two fronts. First, several mediators have
S I G N I F I C A N C E
Cachexia, or muscle wasting, is a debilitating consequence of cancer. Although this syndrome is often related to late-stage disease,
effective cachexia therapy may improve patient response to cancer treatment, impacting quality of life and survival. We find that
wasting in cancer is linked to a dysfunctional dystrophin glycoprotein complex (DGC), a membrane structure associated with
muscular dystrophy. Tumor progression leads to dystrophin reduction and aberrant DGC glycosylation. Tumor-induced muscle wast-
ing is also enhanced in dystrophin null mice but spared in dystrophin transgenic animals. Furthermore, DGC deregulation is also
present in cachectic patients with gastroesophageal adenocarcinoma. Thus, DGC dysfunction is an underlying cause of wasting in
both muscular dystrophy and cancer, a finding that may prove useful for anticachexia therapy.
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been identified, including proinflammatory cytokines TNFα,
IFNγ, and IL-6, as well as the tumor secreted proteolysis-induc-
ing factor (PIF) (Argiles and Lopez-Soriano, 1999; Reid and Li,
2001; Tisdale, 2002). Although the nature and regulation of
these cachectic products are distinct, a common mode of ac-
tion in mediating wasting is through the loss of myofibrillar pro-
teins, in particular myosin heavy chain (MyHC) (Acharyya et al.,
2004). Second, cachexia mediators reduce lean muscle mass
by altering the homeostasis between synthesis and degrada-
tion of muscle protein (Rennie et al., 2004). Protein degradation
is largely regulated by the lysosomal and ubiquitin proteasome
pathways (Farges et al., 2002; Hasselgren and Fischer, 2001;
Jackman and Kandarian, 2004; Lecker et al., 1999). Genes
regulating proteasome-mediated proteolysis are elevated in
muscles from animal models of cancer cachexia as well as in
patients (Temparis et al., 1994; Williams et al., 1999). Identifica-
tion of two muscle-specific E3 ubiquitin ligases, MuRF1 and
A R T I C L E
atrogin-1/MAFbx, have further demonstrated the predominant
contribution of the proteasome pathway in muscle wasting
(Bodine et al., 2001; Gomes et al., 2001). Furthermore, Foxo
transcription factors were recently shown to regulate expres-
sion of these ligases in various models of atrophy (Sandri et
al., 2004; Stitt et al., 2004). However, despite these insights
into the molecular etiology of this syndrome, effective cancer
cachexia therapy remains elusive.
A separate group of muscle disorders also characterized
by severe muscle wasting are the muscular dystrophies.
Duchenne/Becker and several forms of limb-girdle muscular
dystrophy are linked to mutations in genes that encode
components of the dystrophin glycoprotein complex (DGC), a
multiprotein structure associated with myofiber membranes
(Dalkilic and Kunkel, 2003; Durbeej and Campbell, 2002; Blake
et al., 2002). At the core of the DGC is dystrophin, a large 427
kDa protein associating with the cytoskeleton through interac-
tion with F-actin at its amino terminus and connection to the
sarcolemma by binding to β-dystroglycan (β-DG) at its carboxyl
end (Ervasti et al., 1990; Hoffman et al., 1987; Yoshida and
Ozawa, 1990). β-DG is bound to α-dystroglycan (α-DG), which
itself is linked to the extracellular matrix by its interactions with
laminin-2. The DGC therefore forms a strong mechanical link
between the cytoskeleton and the extracellular matrix, protect-
ing cells from contraction-induced injuries (Campbell and Stull,
2003). In addition, the DGC maintains an active signal trans-
duction pathway by interacting with Grb2 and nNOS (Rando,
2001). Mutations in dystrophin or other members of the DGC
disrupt the mechanical linkage and/or signaling pathway(s), re-
sulting in membrane damage, necrosis, and eventual muscle
wasting (Lapidos et al., 2004).
Although the underlying mechanisms of muscle cachexia ap-
pear nonoverlapping to those in muscular dystrophy, our cur-
rent findings suggest that a dysfunctional DGC might be a
common link between these two disease states.
Results
Murine models recapitulate histological features
of human cancer cachexia
To gain insight into the mechanisms underlying muscle wasting
in cancer, we performed histological analysis of cachectic
muscles in tumor-bearing mice. In biopsies from cancer pa-
tients, wasting results from atrophy selectively in type II fibers.
Increased vascularization is observed, but overt signs of in-
flammation or apoptosis are typically absent (Karpati and Car-
penter, 2001; Marin and Denny-Brown, 1962; Mendell and En-
gel, 1971). Similarly, muscles from mice bearing subcutaneous
colon-26 (C-26) tumors were severely atrophic, exhibiting 45%
reduction in mean fiber diameter in tibialis anterior (TA) (Figure
1A), with similar atrophy observed in gastrocnemius (Figure 1A)
and quadriceps (data not shown). Myofibrillar ATPase staining
of the mixed fiber type gastrocnemius muscle confirmed that
atrophic fibers were selectively type II in origin (Figure 1B).
Mean diameter reductions of these fibers were 40% (40.8 ± 0.3
m in control compared to 24.3 ± 0.2 m in tumor-bearing
mice), while type I fibers remained relatively unchanged (35.7 ±
0.4 m in controls to 36.9 ± 0.4 m in tumor mice) (Figure 1C).
ATPase staining also revealed the presence of increased blood
vessels in cachectic muscles, which was confirmed by the en-
dothelial cell-specific marker von Willebrand factor (Figure 1A).
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Figure 1. Histological features of the C-26 murine model of cancer
cachexia
A: H&E-stained cryosections of TA (Aa and Ab) and gastrocnemius (Ac and
Ad) muscles were analyzed from control mice or mice injected with C-26
cells after 25 days (scale bar, 25 m). Gastrocnemius sections (Ae and Af)
were stained with myofibrillar ATPase (pH 4.6) to differentiate slow (type I,
dark) and fast (type II, intermediate to light staining) fibers (scale bar, 50
m). Immunohistochemical analysis of muscle sections with antibody
against von Willebrand factor (VWF) in saline- or tumor-injected mice (Ag
and Ah) (scale bar, 100 m). TUNEL assays were performed on muscle sec-
tions (Ai and Aj) using thymus as positive control (inset).
B: Fiber diameter was measured from muscle sections stained with ATPase
from control and C-26 tumor mice (n = 3 each) at 25 days.
C: Similar analysis as in B was repeated with type I fibers.
Although infiltration of inflammatory cells is often a conse-
quence of increased vascularization, no statistically significant
differences were observed in the numbers of lymphocytes or
macrophages between control and C-26 muscles (data not
shown). Moreover, TUNEL staining revealed little if any evi-
dence of apoptosis (Figure 1A). Taken together, our analysis
suggest that the C-26 model faithfully recapitulates the clinical
features of cancer-induced muscle wasting (Karpati and Car-
penter, 2001), indicating that the mechanisms regulating mus-
cle breakdown in this murine model are likely to overlap with
those present in the human condition.
Cachectic fibers show abnormal membrane morphology
Upon closer histological examination, alterations in membrane
structure were apparent in muscles from C-26 tumor-bearing
mice. As compared to the smooth and well-defined membrane
bordering each myofiber in control muscles, membranes in
cachectic muscles appeared wrinkled and irregular (Figure 2A).
This phenotype was confirmed by electron microscopy and
laminin staining, giving an early indication that sarcolemma and
the associated basal lamina from cachectic muscles were ab-
A R T I C L E
Figure 2. Tumor-bearing mice exhibit abnormal
muscle membranes
A: Muscles from control (Aa) or mice bearing
tumors (Ab) for 20 days were stained with tolu-
idine blue (arrowheads denote fiber edge;
scale bar, 2.5 m). Ultrathin sections of control
and tumor-bearing mice were analyzed by EM
(Ac–Af) (scale bar, 0.2 m). Longitudinal sec-
tions (Ad) revealed normal Z band streams in
cachectic muscles, while cross-sections (Af)
showed evidence of myofibrillar disarray. Lami-
nin immunofluorescence was performed on
sections from control (Ag) or C-26-bearing (Ah)
mice (scale bars = 10 m).
B: Control and C-26 tumor mice were injected
intraperitoneally with EBD for 24 hr. Gross mor-
phology of hindlimb was examined (top panel),
and sections of TA muscles were subsequently
prepared and visualized by fluorescence; scale
bar, 100 m (inset depicts EBD-filled fibers).
normal (Figure 2A). Such morphological changes raised the in-
triguing possibility that membrane damage could be associ-
ated with the pathogenesis of cancer cachexia. To test this,
Evans blue dye (EBD) uptake was used to measure membrane
integrity. EBD is normally membrane impermeable, but in dam-
aged myofibers this dye penetrates the sarcolemma and accu-
mulates in the cytoplasm (Straub et al., 1997). Gross morpho-
logical analysis of muscles from tumor mice injected with EBD
revealed visibly higher uptake of the dye over that in control
mice (Figure 2B). To determine the precise dye localization, TA
muscles were sectioned and histologically examined. Consis-
tent with gross analysis, muscles from cachectic mice ab-
sorbed greater amounts of dye, and in some, albeit rare sec-
tions, dye infiltration occurred in the cytoplasm of clustered
myofibers. Dye uptake did not simply result from increased
vasculature in cachectic muscles, since uptake was negligible
in both TA and the more highly vascular soleus muscles in con-
trol mice (Figure S1 in the Supplemental Data available with
this article online). Serum creatine kinase (CK) is also used as
an indicator of weakened membranes (Durbeej and Campbell,
2002). However, in C-26-bearing mice CK levels were only
moderately elevated over that of controls (Figure S1), indicating
that although tumor burden causes alterations to muscle mem-
branes or associated basal lamina, the severity of this damage
is not sufficient to cause a complete permeation of EBD or
release of intracellular proteins.
Regulation of the DGC is associated
with cancer cachexia
The DGC plays a major role in regulating membrane integrity,
and mutations in this complex result in different forms of mus-
cular dystrophies (Campbell and Stull, 2003). Although the
causative mechanisms of muscular dystrophies and cachexia
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are considered distinct, given the membrane irregularities ob-
served in tumor-bearing mice, we considered that the DGC
might also be involved in the regulation of cancer cachexia. To
initiate this analysis, we examined the potential regulation of
the DGC core member, dystrophin. Western analysis revealed
that dystrophin was reduced in muscles from tumor-bearing
mice (Figure 3A) at a time that preceded reductions in mean
fiber diameter (Figure 7B). Immunofluorescence further showed
that, in comparison to the uniform staining of control fibers,
dystrophin expression in tumor mice was discontinuous or
completely absent along the sarcolemma of many fibers (Fig-
ure 3B). Changes at the protein level did not correlate with
mRNA (Figure 3A), suggesting that downregulation of dystrophin
in tumor-bearing mice is posttranscriptional. In Duchenne mus-
cular dystrophy (DMD), loss of dystrophin is often associated
with compensatory upregulation of its autosomal homolog
utrophin (Tinsley et al., 1998). Muscles from tumor-bearing
mice showed similar induction of utrophin, which by Western
resolved as two forms (Figures 3A and 3B). Although the nature
of these forms requires further characterization, the results
nevertheless support the deregulation of dystrophin in cachec-
tic muscles. Conditions where dystrophin expression is lost,
such as in muscular dystrophies or enterovirus-mediated car-
diomyopathy, typically result in the concurrent downregulation
of other DGC members (Badorff et al., 1999; Durbeej and
Campbell, 2002). This was not the case in cancer cachexia,
since expression of α-DG, β-DG, α-sarcoglycan (SG), β-SG,
δ-SG, and dysferlin was unaltered (Figure 3C), and changes
were not detected in caveolin-3, syntrophin, and Grb2 (data
not shown).
Prominently detected in muscles from tumor-bearing mice,
however, was the presence of a higher migrating band for both
β-DG and β-SG (Figure 3C). Since aberrant posttranslational
A R T I C L E
Figure 3. Tumor-induced alterations in the DGC
A: Analysis of dystrophin (Dys) and utrophin (Utr)
by Westerns or Dys and GAPDH by Northerns
from TA muscles harvested at indicated days
following either saline (control) or C-26 tumor
cell injections.
B: Immunofluorescence on TA muscles from day
12 control and C-26 tumor mice stained with
Dys and Utr (scale bar, 20 m).
C: TA muscles were collected from C-26 tumor
mice at indicated days, and immunoblots were
performed probing for DGC members: Dys; α-
and β-DG; α-, β-, and δ-SG; dysferlin (Dysf); and
α-tubulin as loading control. Arrowheads indi-
cate higher migrating forms of β-DG and β-SG.
D: Tissue lysates from control and cachectic
muscles were either untreated (−) or treated (+)
with PNGaseF or λ-phosphatase (PPase) and
subsequently probed for β-DG with C-terminal
(Novacastra) or N-terminal (BD, clone 56) anti-
bodies.
E: Western for β-SG in C-26 lysates untreated or
treated with PNGaseF.
F: Immunofluorescence staining for β-DG in TA
sections from day 14 control and C-26 tumor
mice (scale bar, 50 m).
G: Westerns for β-DG and β-SG in TA, quadriceps
(quad), and gastrocnemius (gastroc) muscles
from saline (control)- and LLC-injected mice.
H: Western for β-DG in C-26 and LLC cultured
cells and tumors, with tubulin used as a loading
control. Arrows indicate β-DG-processed (lower),
endogenous (middle), and hyperglycosylated
(top) forms.
glycosylation of dystroglycan proteins is known to occur in var-
ious disease states (Jing et al., 2004; Michele et al., 2002), we
investigated the possibility that β-DG and β-SG were subjected
to a similar deregulation in cancer cachexia. Consistent with
previous findings, treatment of control muscle lysate with gly-
cosidase PNGaseF decreased the 43 kDa basally glycosylated
form of β-DG by approximately 5 kDa (Holt et al., 2000) and,
as also reported, caused a nonspecific reduction of β-DG
(Esapa et al., 2003) (Figure 3D). In cachectic muscles, the 43
kDa form of β-DG was also shifted with PNGaseF, but impor-
tantly, so was the higher form. In addition, the almost complete
disappearance of the higher migrating band corresponded with
a concomitant increase of endogenous protein, suggesting
that this higher band represents a hyperglycosylated form of
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β-DG. A decrease in the higher form was also detected when
PNGaseF-treated lysates were probed with either a β-DG anti-
body generated to the identical epitope in the carboxyl termi-
nus (MANDAG 2, clone 7D11) (data not shown) or with an
amino-terminal antibody that favored recognition of the higher
form (clone 56) (Figure 3D). It is possible that other posttransla-
tional modifications occur in β-DG, but such modifications are
not due to phosphorylation, since no change in β-DG mobility
was observed when lysates were treated with phosphatase
(Figure 3D). In an analogous fashion, PNGaseF-sensitive glyco-
sylation was also reproducibly detected in the higher form of
β-SG (Figure 3E). The fact that no alterations were detected in
other glycosylated DGC members, α-SG and δ-SG (Figure 3C),
or non-DGC glycosylated proteins such as β1 subunit of
A R T I C L E
ATPase and NCAM (Figure S2), argued that aberrant glycosyla-
tion of β-DG and β-SG was specific to these DGC proteins.
Furthermore, although alterations in glycosylation can result in
abnormal trafficking of DGC proteins (Holt et al., 2000), altered
glycosylation of β-DG and β-SG did not appear to affect the
cellular localization of these proteins (Figure 3F). To evaluate if
these findings could be extended to another model of cancer
cachexia, β-DG and β-SG were monitored in mice bearing
Lewis lung carcinoma (LLC). Consistent with C-26 tumors, LLC
promoted altered glycosylation of β-DG and β-SG in various
muscle groups (Figure 3G), correlating with reduced muscle
mass and decreased dystrophin expression (Figure S2). Since
β-DG processing is associated with cellular transformation
(Jing et al., 2004), we also analyzed whether a similar deregula-
tion occurred in C-26 and LLC tumors. Results showed that,
although such processing did occur, interestingly, hyperglyco-
sylation of β-DG was also apparent in tumors, but not cultured
cells (Figure 3H), indicating that tumor communication with the
microenvironment or distant target tissues is required for modi-
fications of this DGC protein. Collectively, these results demon-
strate that alterations in the DGC are characteristic of a tumor-
induced wasting state.
Regulation of the DGC is specific to cachectic fibers
Having established a potential link between the DGC and tu-
mor-regulated muscle wasting, we next sought to address
whether DGC regulation was selective to atrophic fibers. For
this determination, laser capture microdissection (LCM) was
performed on muscle sections from control and C-26 tumor-
bearing mice. In order to test the validity of this approach,
β-DG Westerns were performed comparing LCM-captured fi-
bers to muscle homogenates. As with tissue homogenates, a
clear increase in hyperglycosylation of β-DG was detected in
cachectic fibers isolated by LCM (Figure 4A). Next, LCM was
used to compare DGC proteins between cachectic and non-
cachectic fibers captured from the same wasted muscle. Re-
sults showed reproducibly higher intensity of β-DG and β-SG
glycosylation in fibers deemed cachectic by a mean diameter
of less than 30 m (Figure 4B; dotted boundary). In compari-
son, troponin expression was unaltered among these fiber
groups. Since tumor-induced atrophy is selective to type II fi-
bers (Figure 1), we investigated if DGC alterations were fiber
type specific. C-26 derived gastrocnemius muscles were sec-
tioned and subsequently stained for myosin ATPase or slow
MyHC to distinguish type I from type II fibers. LCM was then
performed on serial sections, and Westerns were repeated. Re-
sults showed that, although a faint hyperglycosylated form of
β-DG appeared in type I fibers (most likely reflecting type II
fibers present within type I groupings), this glycosylation pat-
tern was noticeably enhanced in captured type II fibers (Figure
4C). To verify this selectivity, double immunofluorescence of
dystrophin and MyHC-I was performed on sections from tu-
mor-bearing mice. Results showed that, although some reduc-
tion in dystrophin occurred in type I fibers, the predominant
reduction was type II associated (Figure 4D). Together, these
data suggest that regulation of the DGC is selective to the
atrophic state of type II fibers in response to tumor burden.
Tumor-induced functional loss of the DGC
To understand the functional relevance of DGC regulation, we
assessed binding interactions between DGC proteins from
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Figure 4. DGC alterations are selective to cachectic fibers and lead to loss
of interactions
A: β-DG Westerns from control and tumor mice detected from tissue lysates
or lysates prepared from approximately 5000 muscle fibers captured by
LCM. Arrowhead marks altered β-DG glycosylation.
B: LCM was performed based on fiber size from TA muscles of tumor-bear-
ing mice (dotted boundary represents fibers <30 m in diameter) (scale
bar, 25 m), followed by Westerns for β-DG, β-SG, and troponin (Tn). Arrow-
heads indicate hyperglycosylation.
C: Areas for microdissection were selected upon staining sections of gas-
trocnemius muscles from tumor mice with ATPase (pH 4.2) stain (dotted
boundary represents type I fibers) (scale bar, 200 m). LCM was performed
on serial sections, and β-DG and MyHC type I were subsequently probed
by Westerns.
D: Double immunofluorescence of muscle from day 10 C-26-injected mice
with dystrophin (red) and MyHC type I (blue) (scale bar, 10 m).
E: Ligand overlay assays performed on WGA-enriched muscle homoge-
nates from control and C-26 tumor mice.
F: Coimmunoprecipitations (IP) were performed using a β-DG antibody,
and interacting proteins were detected by immunoblotting (IB) probing for
α-DG, dystrophin (Dys), and Grb-2. Levels of proteins are shown by corre-
sponding Westerns.
control and tumor mice. In the DGC, α-DG serves as a receptor
binding laminin-2 in the extracellular matrix (Campbell and
Stull, 2003). Using ligand overlay assays, a significant reduc-
tion in laminin-α-DG binding was observed in C-26 cachec-
tic muscles (Figure 4E). Furthermore, coimmunoprecipitation
analysis revealed pronounced decreases in interactions be-
tween α-DG and β-DG and between β-DG and dystrophin in
tumor mice (Figure 4F). Corresponding Westerns confirmed
that loss of interactions was associated with decreases in
dystrophin and alterations in β-DG. Regulation of DGC interac-
A R T I C L E
Figure 5. Wasting is enhanced in tumor-bearing
mdx mice
A: Saline or C-26 tumor cells (5 × 105 cells) were
injected subcutaneously into the right flank
of C57BL/10/CD2F1 (wild-type) or mdx/CD2F1
male mice with (n = 6) or without (n = 8) pair
feeding. After 2–3 weeks, gastrocnemius muscles
were weighed. Muscle mass loss from tumor
mice was expressed as a percentage of con-
trols, which was set to a value of 100% (asterisk
denotes statistically significant differences, p <
0.05; similar statistically significant results were
obtained with TA and quadriceps muscles).
B: Westerns probing for myofibrillar proteins from
wild-type and mdx mice with and without C-26
tumors after 14 days.
C: Muscles from C57BL/6 or mdx/C57BL/6 mice
injected intramuscularly with either saline con-
trol or LLC cells were weighed and harvested
after 14 days. Mass from LLC muscles is ex-
pressed as percentage of controls, which was
set at 100% (asterisk denotes p < 0.05).
D: H&E stains of gastrocnemius muscle from
6-week-old mdx or mdx mice bearing C-26 tu-
mors for 14 days (scale bar, 50 m).
E: Fiber diameter was measured from H&E sec-
tions in D.
F: Real-time RT-PCR of CD68 from wild-type, sa-
line-injected, or C-26 tumor mdx mice. Percent
calcifications of muscles stained with von Kossa
from mdx mice injected with saline (set at 100%)
and C-26 tumor cells. IL-6 ELISA from serum of
wild-type and mdx mice with and without
tumors.
For graphs, data are plotted as mean ± SEM.
tions appeared selective, since no change in the affinity of
β-DG and Grb2 was detected. These results show that tumor-
induced muscle wasting correlates with dissociation of the
DGC along the extracellular matrix-cytoskeleton axis, possibly
resulting from the deregulation of dystrophin, β-DG, and β-SG.
Loss of DGC enhances cancer-induced muscle atrophy
To firmly establish the contribution of the DGC in cancer
cachexia, we took advantage of the mdx murine model of
DMD. mdx mice have a mutation that codes for a premature
stop codon in the X-linked dystrophin gene (Sicinski et al.,
1989) resulting in the loss of dystrophin and associated DGC
proteins (Ohlendieck and Campbell, 1991). Although the mdx
pathology resembles the early phases of DMD, relatively little
muscle loss actually occurs in these mice due to the high rate
of muscle regeneration and hypertrophy in response to the on-
going cycles of degeneration (Durbeej and Campbell, 2002).
Thus, C57/BL10 mdx mice were crossed into a CD2F1 back-
ground, and C-26 tumors were administered to wild-type and
mdx males. Although mice exhibited comparable tumor bur-
den, muscle loss was accentuated in mdx/CD2F1 mice com-
pared to wild-type C57BL10/CD2F1 littermates (Figure 5A).
Daily cage monitoring indicated that muscle loss in mdx mice
was not due to asthenia or anorexia (Figure S3), and consistent
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with this latter observation, muscle wasting was also enhanced
in mdx mice over wild-type in pair-fed conditions (Figure 5A).
Greater reduction in muscle mass correlated with a decrease
in MyHC (Figure 5B), indicative of a bona fide wasting state,
and as previously described (Acharyya et al., 2004) this regula-
tion was selective over other core myofibrillar proteins. Impor-
tantly, fiber membranes from mdxmice alone were visibly irreg-
ular, and DGC proteins were also aberrantly glycosylated
(Figure S4), suggesting that loss of dystrophin leads to β-DG
and β-SG alterations. Furthermore, these effects were not re-
stricted to the C-26 model, since a significant decrease in mus-
cle mass also occurred in mdx mice bearing LLC tumors (Fig-
ure 5C).
To elucidate how the loss of DGC in mdx mice exacerbated
muscle wasting in response to tumor factors, histological
analysis was performed. Consistent with reduced mass, fibers
from C-26 mdx mice exhibited substantial atrophy with an
average fiber diameter reduction of 33% (40.0 ± 0.46 m in
controls compared to 26.9 ± 0.21 m in mdx tumor mice) (Fig-
ures 5D and 5E). Since inflammation and abnormal calcium in-
flux are considered important mediators of wasting in DMD
(Blake et al., 2002), we assessed whether these factors were
responsible for the increased muscle loss in the tumor-bearing
state. As reported (Chen et al., 2000), the CD68 inflammatory
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marker was pronouncedly elevated in mdx mice, but no further
regulation occurred in mice with C-26 tumors (Figure 5F). Simi-
larly, no differences were seen in dystrophic calcifications be-
tween tumor and nontumor mdx animals. Tumor mdx mice did,
however, exhibit higher circulating levels of IL-6, consistent
with suspected involvement of this cytokine in C-26-mediated
atrophy (Argiles and Lopez-Soriano, 1999). These data there-
fore suggest that loss of the DGC exacerbates tumor-induced
wasting resulting from an atrophic rather than a dystrophy-
associated condition.
Muscle-specific dystrophin expression blocks
tumor-induced muscle wasting
Next, we reasoned that, if a dysfunctional DGC is relevant in
cancer cachexia, restoration of this complex would rescue the
cachectic phenotype in response to tumor burden. To test this,
transgenic mice expressing a dystrophin minigene in skeletal
muscle (17-48) (Phelps et al., 1995) were crossed into a
CD2F1 background, and C-26 tumors were administered. As
with mdx mice, tumor growth and food intake (Figure S5) were
comparable between wild-type and 17-48 animals. However,
while appreciable muscle mass was lost in wild-type mice, little
to no decrease in mass and fiber diameter occurred in
dystrophin transgenic mice (Figures 6A and 6B). EM and lami-
nin staining also revealed that muscles from 17-48 tumor
mice were spared of membrane abnormalities, and overlay as-
says showed restored DGC interactions (Figures 6C and 6D).
Furthermore, assessment of muscle function showed that wild-
type mice with tumors had approximately 30% reduction in
hindlimb grip strength (1.02 ± 0.14 N for controls and 0.70 ±
0.15 N for C-26 tumor mice) (Figure 6E), while no differences
were observed between control and dystrophin transgenic
mice (0.94 ± 0.24 N to 0.93 ± 0.13 N, respectively). Taken to-
gether, these results argue that DGC restoration can both struc-
turally and functionally block tumor-induced muscle changes.
DGC dysfunction mediates the induction of muscle E3
ubiquitin ligases
To assess the significance of a dysfunctional DGC in cachexia,
we examined whether other factors involved in the mainte-
nance of muscle mass were equally affected by a tumor burden
state. Although studies support the role of PI(3)K/Akt signaling
in regulating muscle hypertrophy (Glass, 2003), at least in the
C-26 model no significant differences in activated Akt were de-
tected in either gastrocnemius or TA (Figure 7A and data not
shown), nor were changes seen in MAPK. Cachectic muscles,
however, displayed a pronounced increase in p70S6K activity
that might have been due to the accumulation of amino acids
released from catabolized proteins (Liu et al., 2004). Another
signaling pathway whose activation has been shown to be re-
quired for muscle wasting is NF-κB (Cai et al., 2004; Guttridge
et al., 2000; Hunter and Kandarian, 2004). Consistent with
these findings, NF-κB activity was also reproducibly elevated
in cachectic muscles over that of controls (Figure 7A). Among
the degradation pathways, the ubiquitin proteasome system
regulates muscle atrophy via the induction of muscle E3 li-
gases in various catabolic states including cancer (Lecker et
al., 2004), and E3 ligase requirement has been demonstrated
in response to glucocorticoid treatment (Bodine et al., 2001),
and more recently to chronically stimulated NF-κB signaling
(Cai et al., 2004). To further investigate the role of the protea-
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Figure 6. Wasting is spared in tumor-bearing dystrophin transgenic mice
A: TA, gastrocnemius (gastroc), and quadriceps (quad) muscles from wild-
type (C57BL/10/CD2F1; WT) and 17-48/CD2F1 transgenic (Tgdys) mice in-
jected with either saline alone (control) or C-26 cells were harvested and
weighed 20–21 days after injection (minimum of n = 6 for each group).
Muscle loss is expressed as a percentage of control muscle mass, set to a
value of 100% (asterisk denotes p < 0.05).
B: Fiber diameter of gastrocnemius muscles from mice shown in A (similar
results were obtained with TA and quadriceps muscles).
C: Cross-sections of muscles from wild-type (Ca) or 17-48/CD2F1 trans-
genic (Cb) mice both bearing tumors were prepared and analyzed by EM
(scale bar, 0.2 m), or sections from wild-type (Cc) and dystrophin trans-
genic mice (Cd) were stained for laminin (scale bar, 20 m).
D: Muscles from mice as in C were homogenized, and laminin overlay as-
says were performed (cont, control).
E: Hindlimb grip strengths for wild-type (WT) and 17-48/CD2F1 transgenic
(Tgdys) mice injected with PBS (control) or C-26 tumor cells (asterisk denotes
p = 0.051).
For graphs, data are plotted as mean ± SEM.
some system in tumor-bearing mice, we performed a time
course analysis of E3 expression in relation to the onset of
muscle atrophy. Results showed that MuRF1 was induced
within 10 days following tumor cell inoculum, preceding the
initial reduction in fiber size (Figure 7B). Interestingly, this in-
duction occurred around the same time that alterations in the
DGC were detected (Figure 3). This raised the intriguing possi-
bility that DGC dysfunction may either regulate or be itself reg-
ulated by the proteasome. To test this, MuRF1 expression and
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Figure 7. Tumor-induced ubiquitin ligase expres-
sion is blocked in dystrophin transgenic mice
A: Gastrocnemius muscles from saline- and
C-26-injected CD2F1 mice after 20 days were
homogenized and examined by immunoblots
probing for indicated signaling proteins and tu-
bulin as a loading control, or examined by EMSA
for NF-κB activity.
B: Northern of MuRF1 in muscles isolated from
tumor mice at indicated days. Expression of
MuRF1 was quantitated by phosphoimaging
and normalized to GAPDH. The degree of
MuRF1 induction was plotted against the per-
centage of muscle atrophy determined by
measuring fiber diameter on the same days.
C: Northern (MuRF1, atrogin-1/MAFbx, GAPDH)
and EMSA (NF-κB) analyses from muscles of
C57BL/10/CD2F1 wild-type or 17-48/CD2F1 dys-
trophin transgenic mice injected with either sa-
line (control) or C-26 tumor cells (n = 9).
atrogin-1/MAFbx expression were examined in tumor-bearing
C57BL10/CD2F1 wild-type and dystrophin 17-48 transgenic
animals. Results showed that while both E3 ligases were
strongly induced in wild-type mice, this regulation was sub-
stantially reduced in muscles with rescued DGC (Figure 7C;
observed in 7/9 tumor-bearing transgenics). In contrast, NF-
κB was increased in both C-26 tumor-bearing wild-type and
dystrophin transgenic mice. Collectively, results imply that
DGC dysfunction regulates the ubiquitin proteasome system in
an NF-κB-independent manner.
DGC is deregulated in cancer patients with cachexia
Finally, we addressed whether DGC dysfunction was present in
patients with cancer cachexia. DGC was examined in muscle
biopsies from patients with gastrointestinal cancers, since
such patients commonly undergo extensive weight loss (An-
dreyev et al., 1998) and demonstrate poor quality of life and
reduced survival (Deans and Wigmore, 2005). Compared to
weight-stable healthy controls, results showed that carcinoma
patients with marked weight loss had dramatic reductions in
dystrophin (Figure 8A; Table S1). Ponceau S staining confirmed
that this loss was not due to a general reduction in total pro-
tein. In the murine models of cachexia, decreases in dystrophin
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were associated with increased glycosylation of β-DG and
β-SG. Likewise, dystrophin reduction in patients was tightly
linked with hyperglycosylation of DGC proteins, to the extent
that a direct correlation was clearly discernable between dys-
trophin reduction and β-DG and β-SG glycosylation (termed
deregulated DGC).
A more extensive analysis from 14 control individuals and
27 histologically confirmed gastroesophageal adenocarcinoma
(ACC) patients (11 esophageal, 12 stomach, 4 esophagogastric
junction) revealed that DGC deregulation was completely ab-
sent in controls but present in 16 (59%) ACC samples, thus
indicating a disease association. Significantly, when stringent
parameters of cachexia were applied, defined by C-reactive
protein levels > 10 mg/l and weight loss > 10% of preillness
weight (Deans and Wigmore, 2005), 10/11 (91%) patients ex-
hibited prominent DGC deregulation (χ2 = 5.593; df = 1; p =
0.02) (Figure 8B). Equally striking was that, of ten nonsurviving
cases, 10/10 (100%) were also positive DGC deregulation.
Kaplan-Meier survival analysis demonstrated a statistically sig-
nificant difference between normal and deregulated DGC
cases (p = 0.006 by log rank test) (Figure 8C). Moreover, analo-
gous to the C-26 model, ligand overlay assays from carcinoma
patients revealed decreases in DGC association (Figure 8D).
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Figure 8. DGC dysfunction is associated with cachexia in gastrointestinal
carcinoma patients
A: Rectus abdominus biopsies from control (cont.) and adenocarcinoma
patients were homogenized and analyzed by Westerns probing for Dys,
β-DG, and β-SG. Upper band denotes hyperglycosylated products.
B: The relationship between cachexia and survival with DGC deregulation
in healthy control (n = 14) and ACC patients (n = 27).
C: Kaplan-Meier survival analysis comparing normal and deregulated
DGC by log rank test. Censored data points are represented as vertical
bars.
D: Ligand overlay assays performed with muscles from control and ACC
patients.
E: Co-IPs performed with samples as in D with a skeletal actin antibody
and subsequently immunoblotted for MyHC. Corresponding actin Western
is shown.
Results also highlighted that wasting was not selective to the
DGC, since similar deregulation occurred in actin-myosin com-
plexes (Figure 8E). Nevertheless, these results demonstrate
that gastrointestinal cancer patients exhibit dysfunctional DGC
that correlates positively with cachexia and inversely with sur-
vival.
Discussion
Cancer is often complicated by cachexia that interferes with
treatment response and shortens survival (Tisdale, 2002). The
findings in this study provide important insight into the mecha-
nism of this disorder by revealing that tumor-induced DGC dys-
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function is a contributing factor in muscle wasting. Although
cancer cachexia and muscular dystrophy involve chronic mus-
cle loss, from an etiological and molecular standpoint, the
causative mechanisms of these disorders are considered to be
largely nonoverlapping (McKinnell and Rudnicki, 2004). This is
because muscular dystrophies are genetic in origin, with nu-
merous mutations mapping to dystrophin and other DGC
members. Moreover, dystrophy includes lymphocyte and mac-
rophage recruitment, necrosis, muscle regeneration, apopto-
sis, and fibrosis that together culminate in a degenerative state
(Campbell and Stull, 2003; Dalkilic and Kunkel, 2003). In con-
trast, a genetic disposition for muscle wasting in cancer has
not been described, and biopsies from carcinoma patients and
a murine model presented here reveal little if any evidence of
infiltrating cells, necrosis, regeneration, apoptosis, or fibrosis.
Rather, muscle loss due to malignancy exhibits pronounced
fiber atrophy and increased vascularization, which most likely
serves to facilitate circulation of tumor factors and host cyto-
kines in the microenvironment.
Despite differences between cachexia and muscular dystro-
phy, our findings indicate that one potentially important com-
monality is the abnormality of fiber membranes resulting from
a deregulated DGC. Microscopy analysis revealed that muscle
membranes from cachectic mice were highly wrinkled and ir-
regular. Interestingly, irregularities of membranes have also
been reported in DMD patients as secondary consequences of
DGC dysfunction (Mokri and Engel, 1975). In dystrophy, DGC
mutations are thought to weaken membranes, measured by
EBD uptake and CK release (Durbeej and Campbell, 2002). In
muscles from C-26 mice, EBD membrane association was
clearly visible, but only on a few occasions did the dye accu-
mulate in the cytoplasm, and CK release was rarely noted. This
indicates that alterations in fiber membranes occur in cachec-
tic fibers, but to a lesser degree than in dystrophic muscles.
We speculate that this difference in damage correlates with the
degree of dysfunction exhibited by the DGC. In DMD, loss of
dystrophin leads to a reduction of DG and SG proteins, result-
ing in the functional breakdown of the DGC (Blake et al., 2002).
In the C-26 model, dystrophin expression is reduced but not
eliminated, and the loss of other DGC proteins is not observed.
Nevertheless, evidence from mdx and dystrophin transgenic
mice indicates that alterations in the DGC from developing tu-
mors are sufficient to induce membrane damage that may
function as a cause and not simply a consequence of muscle
atrophy. Gastrointestinal cancers, specifically gastroesopha-
geal ACC, are the most highly associated with cachexia and
have the fastest increasing incidence of any solid tumor in
Europe and America (Lagergren, 2005). Given the extent to
which dystrophin was reduced in patients with these types of
cancers, it will be interesting to examine how this regulation
impacts the expression of other DGC members and the overall
integrity of muscle membranes.
In conjunction with dystrophin regulation, two other mem-
bers of the DGC, β-DG and β-SG, were aberrantly glycosylated
in tumor cachexia models and cachectic patients. Results
showing that such glycosylation also occur in mdx muscle is
genetic evidence that loss of dystrophin expression leads to
aberrant glycosylation in DGC proteins. The data further re-
vealed that DGC deregulation correlated with a significant loss
in binding among DGC members. We suspect that the de-
crease in dystrophin contributes to the reduction in these in-
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teractions, but further studies are warranted to determine if ab-
errant glycosylation also contributes to DGC dysfunction and
muscle wasting. In certain congenital dystrophies, mutations in
glycosyltransferases decrease rather than increase glycosyla-
tion of DGC proteins (Michele et al., 2002). However, trans-
genic expression of a glycosyltransferase in muscle was also
shown to reduce fiber diameters (Xia et al., 2002). Thus, it is
possible that increases in glycosyltransferase activity in tumor-
bearing mice may be a contributing factor in cachexia.
It is not known at this time whether tumor-induced DGC dys-
function leads to muscle wasting via a breakdown in the me-
chanical link between the extracellular matrix and the cytoskel-
etal network, or through a disruption in the signaling link
between the DGC and MAP kinase or the PI(3)K/Akt pathways
(Rando, 2001). Data showing that β-DG/Grb2 interactions, as
well as Erk and Akt activities, are maintained in cachectic
muscles support a connection between a disrupted mechani-
cal link and muscle atrophy. However, it is equally likely that
tumor-induced alterations in the DGC may abrogate a sepa-
rate, yet to be identified pathway that is critical to promote
wasting. Such a pathway could be the proteasome system,
since studies have established the requirement of muscle-
specific E3 ligases, MuRF1 and atrogin-1/MAFBx, in several
cachectic states (Jackman and Kandarian, 2004). Induction of
these genes leads to polyubiquination and degradation of key
skeletal muscle proteins such as MyHC (Acharyya et al., 2004).
Data showing that MyHC reduction was accentuated in mdx
mice with tumors while muscle atrophy and E3 ubiquitin ligase
induction were blocked in dystrophin transgenic animals argue
for a role of a dysfunctional DGC in proteasome regulation.
Since results indicate that tumor reduction of dystrophin is
posttranscriptional, it is also possible that activation of the pro-
teasome may regulate dystrophin by a feedback mechanism.
Our results support a model in which, during tumor pro-
gression, circulating factors function to reduce dystrophin levels,
leading to aberrant glycosylation of β-DG and β-SG proteins.
These events promote DGC breakdown followed by membrane
abnormalities. A dysfunctional DGC, either alone or in combi-
nation with other deregulated factors associated with an al-
tered membrane or basal lamina, in turn stimulates the induc-
tion of E3 ligase genes and possibly other components of the
proteasome pathway, culminating in a cachectic state. Since
results showed that E3 ligase induction was not completely
blocked in tumor-bearing dystrophin transgenic muscle, while
NF-κB remained activated, this model also predicts that activa-
tion of the proteasome pathway is likely to be dependent on
multiple pathways elicited from tumor and cytokine signaling
receptors.
Collectively, evidence in this study suggests that DGC dys-
function is an important step in cancer cachexia. Since effec-
tive therapies are currently lacking, results also imply that ap-
proaches targeted to restore the DGC in muscular dystrophies
could also be considered as a viable option in designing anti-
cancer cachexia therapy.
Experimental procedures
Mice
Male CD2F1 (BALB/c × DBA/2) mice weighing 22–24 g were used, and C-26
cells were subcutaneously injected in the right flank as described (Acharyya
et al., 2004). mdx mice (C57BL/10 ScSn DMDmdx) and 17-48 (CVBA 3#)
dystrophin transgenic mice (Phelps et al., 1995) were crossed into a CD2F1
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background up to six generations. Mice were housed in the animal facility
at The Ohio State University Comprehensive Cancer Center under conven-
tional conditions with constant temperature and humidity and fed a stan-
dard diet. Treatment of mice was in accordance with the institutional guide-
lines of The Ohio State University Animal Care and Use Committee. For LLC
cachexia, 5 × 105 LLC cells were intramuscularly injected into quadriceps.
Histology and electron microscopy
Muscles were sectioned at 10 M on a cryostat (Leica) and stained with
H&E or with myofibrillar ATPase (pH 4.2 or pH 4.6). Fiber measurements
were obtained from a minimum of 1500 fibers per five to six randomly cho-
sen fields and recorded from the shortest diameter using Axiovision 3.1
software (Zeiss). For EM, muscles were stretched in situ with bone support,
fixed in 3% glutaraldehyde in 0.1 M PBS, and sectioned for analysis on
a Phillips CM 12 microscope as described (Sahenk and Mendell, 1979).
Dystrophic calcifications were detected by von Kossa calcium staining (Bo-
densteiner and Engel, 1978).
Vital staining with EBD
EBD was injected intraperitoneally at 1 mg/10 g body weight. After 24 hr,
mice were sacrificed, and muscles were frozen in liquid nitrogen-cooled
isopentane. Frozen sections were mounted with Antifade reagent (Biomeda)
and observed under a fluorescent microscope. CK assays were performed
as described by the manufacturer (Pointe Scientific Inc).
Immunostaining
Immunofluorescence and immunohistochemistry were performed as pre-
viously described, respectively (Phelps et al., 1995; Hertlein et al., 2005).
Antibodies used were dystrophin (1:40), β-DG (1:200), and β-SG (1:200)
from Novocastra; utrophin (1:100) from BD Pharmingen; von Willebrand fac-
tor (1:300) from Dako; and laminin (1:150) and MyHC I (1:500) from Sigma.
TUNEL assays were performed as described by the manufacturer (Roche).
LCM
Approximately 5000 muscle fibers per group were laser captured using a
Pixcell II LCM system (Arcturus Engineering) from frozen muscle sections.
Fibers were lysed in 15 l of a lysis solution containing 1:1 mixture of SDS
electrophoresis sample buffer and mammalian protein extraction reagent
(Pierce Biotechnology) and subsequently analyzed by Westerns.
Western blot, coimmunoprecipitation, and EMSA
Western and coimmunoprecipitations were performed as previously de-
scribed (Acharyya et al., 2004), with the exception that α-DG incubations
were done with 150 mM NaCl, 20 mM Tris (pH 7.4). Antibodies used were
dystrophin (dys-2;1:50), β-DG (1:100), α-SG (1:200), β-SG (1:200), and dys-
ferlin (1:100) from Novocastra; utrophin (1:250), Grb2 (1:5000), and β-DG
(clone 56; 1:500) from BD Pharmingen; α-DG (IIH6; 1:5000) from K. Camp-
bell (University of Iowa); β-DG (MANDAG 2; 1:100) from G. Morris (North
East Wales Institute); MyHC I and II, actin, troponin, tropomyosin, α-tubulin
(1:1000), laminin (1:500), and syntrophin (1:1000) from Sigma; caveolin-3
(1:2500) from Research Diagnostics Inc.; ATPase β1 (1:50) and NCAM (1:50)
from Developmental Hybridoma Bank; Akt (1:5000), phospho-Akt Ser-473
(1:2000), phospho-p70S6K Thr-389, p70S6K, phospho ERK Thr-202/Tyr-
204, ERK, and phospho p65 Ser-536 from Cell Signaling; and p65
(1:10,000) from Rockland. Patient samples were probed with the 18.4
dystrophin rabbit polyclonal antibody (1:50,000) specific to the carboxy ter-
minus (Cox et al., 1994). For enzymatic deglycosylation and dephosphoryla-
tion analysis, 20 g of tissue lysate was treated with PNGase F or λ phos-
phatase (New England Biolabs) respectively, as recommended by the
manufacturer. EMSA was performed as described (Kumar and Boriek,
2003).
Laminin overlay assays
Laminin overlay assays were performed with 500 g of muscle lysates and
incubated overnight at 4°C with 30 l of wheat germ agglutinin (WGA)-
agarose beads (Vector Labs) as previously described (Michele et al., 2002).
Northern blot and real-time PCR
Northern blots and real-time PCR were performed as described (Hertlein et
al., 2005) with the following primers: CD68, 5#-ACAGGCAGCACAGTGGA
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CATTC-3# forward, 5#-ATGATGAGAGGCAGCAAGAGGG-3# reverse; con-
trol GAPDH, 5#-GCAAATTCAACGGCACAGTCAAG-3# forward, 5#-GGTAC
AAACACTACCCACACTTG-3# reverse.
Grip strength measurement
Total grip strength was measured from control and tumor-bearing mice (21–
22 days after injection) using a Digital Grip Strength Meter (Columbus In-
struments). A minimum of three measurements was taken from each
mouse. Hindlimb grip strength was calculated as the difference between
total and forelimb grip strengths. The observer (M.E.R.B.) was blinded to
the genotype of the mice.
Patients
Muscle biopsies (abdominus rectus) were obtained from men and nonpreg-
nant women between 18 and 80 years of age with informed patient consent.
Diagnosis was based on histological or unequivocal radiological or opera-
tive findings. Healthy, weight-stable subjects undergoing minor surgical pro-
cedures (e.g., inguinal hernia repair) were included in this study. Venous
blood sampling was performed, and serum C-reactive protein was analyzed
by an automated immunoturbidometric method (Abbott Diagnostics). Body
weight was measured with subjects in light clothing without shoes using a
beam scale (Seca). Survival was recorded from the time of initial diagnosis.
Studies involving human subjects were done in accordance with the Lothian
Ethical Committee (UK) and the Institutional Review Boards of the Universi-
ties of Nebraska and Ohio State.
Statistical analysis
All quantitative data are represented as mean ± SEM. Analysis was per-
formed between different groups using a two-tailed Student’s t test for fiber
diameter quantitation. One-way analysis of variance was performed with
Bonferroni post hoc comparison using SPSS V13 for muscle mass and grip
strength quantitation. Statistical significance was set at a p value of <0.05.
Supplemental data
The Supplemental Data include five supplemental figures and one sup-
plemental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/8/5/421/DC1/.
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